AIB1 predicts tumor response to definitive chemoradiotherapy and prognosis in cervical squamous cell carcinoma

Zhao, Zhenfeng; Zhou, Sheng; Li, Wenyu; Zhong, Fei; Zhang, Heping; Sheng, Lei; Li, Yue; Xu, Meng; Xu, Jifei; Zhan, Lei; Bao, Li; Wang, Fan; Xie, Dan; Tong, Zhuting

doi:10.7150/jca.31697

Cited by 4 publications

(4 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, ER signaling is associated with HPV infection and cervical cancer in many aspects, including pro-carcinogenic and anti-carcinogenic relationship [ 127 ]. Recent study found that SRC-3 was more frequently high expressed in cervical cancer (52.7%) compared to normal cervical tissues (30%), and high level of SRC-3 is significantly associated with aggressiveness and chemoradiotherapy resistance [ 47 ]. It suggests that SRC-3 may be considered as a potential target and predictor for the treatment of this disease.…”

Section: Implication Of Src-3 In Cancermentioning

confidence: 99%

SRC-3, a Steroid Receptor Coactivator: Implication in Cancer

Li¹,

Deng²,

Chen³

2021

IJMS

View full text Add to dashboard Cite

Steroid receptor coactivator-3 (SRC-3), also known as amplified in breast cancer 1 (AIB1), is a member of the SRC family. SRC-3 regulates not only the transcriptional activity of nuclear receptors but also many other transcription factors. Besides the essential role of SRC-3 in physiological functions, it also acts as an oncogene to promote multiple aspects of cancer. This review updates the important progress of SRC-3 in carcinogenesis and summarizes its mode of action, which provides clues for cancer therapy.

show abstract

Section: Implication Of Src-3 In Cancermentioning

confidence: 99%

SRC-3, a Steroid Receptor Coactivator: Implication in Cancer

Li¹,

Deng²,

Chen³

2021

IJMS

View full text Add to dashboard Cite

show abstract

“…The most common pathological type of cervical cancer is cervical squamous cell carcinoma (CESC). [1] When patients with CESC are diagnosed and treated in the early stage of the tumor, the chance of survival can be increased and may push the 5-year survival rate to 90%. [2] However, the early symptoms of cervical cancer are not obvious.…”

Section: Introductionmentioning

confidence: 99%

An integrative pan-cancer analysis illustrating the key role of LRP11 in cervical cancer

Fang

Pan

et al. 2023

Medicine

View full text Add to dashboard Cite

Background: Low density lipoprotein receptor-related protein 11 (LRP11) was involved in the progression of several tumors. However, its role in cervical cancer still remains uncertain. Methods: The original tumor data was downloaded from the Cancer Genome Atlas and genotype-tissue expression databases. The expression of LRP11 in normal tissues, tumor tissues and adjacent tissues were evaluated. In addition, we also explored the genetic alteration, prognostic value, and gene function of LRP11. We deeply assessed the interaction between LRP11 and tumor immunity at the pan-cancer level. Finally, research on the association between LRP11 and the resistance of anti-tumor drugs was carried out. Results: LRP11 was highly expressed and played a risk prognostic factor in cervical cancer and a variety of tumors. Enrichment analysis revealed that LRP11 was involved in multiple tumor malignant pathways. Our research also pointed out the unique role between LRP11 and tumor immune microenvironment. The tumor immune microenvironment of patients with high expression of LRP11 are lack of most immune cells, indicating a immune desert tumor microenvironment. The final drug resistant analysis suggested that patients with high expression of LRP11 may be related to the resistance of many anti-tumor drugs. Conclusion: LRP11 was a potential oncogene and prognostic marker in cervical cancer and pan-cancer. Patients with high LRP11 expression may have immune desert tumor microenvironment.

show abstract

“…76 Recent studies from Riegel's laboratory and others indicated a role of AIB1 isoform in the invasion and progression of breast cancer. 74,[77][78][79][80][81][82] While AIB1 plays a clear role in nuclear receptor biology, it has also been implicated in chromatin remodeling. AIB1 was isolated as the p300/CBP cointegrator-associated protein (p/CIP) based on its ability to interact with the C terminus of CBP and has been shown to bind to p300 as well.…”

Section: Introductionmentioning

confidence: 99%

“…Like AIB1, E6AP has been shown to have a role in steroid receptor coactivation and may work in concert with AIB1 for this function 76 . Recent studies from Riegel's laboratory and others indicated a role of AIB1 isoform in the invasion and progression of breast cancer 74,77–82 …”

Section: Introductionmentioning

confidence: 99%

AIB1 is a novel target of the high‐risk HPV E6 protein and a biomarker of cervical cancer progression

Miller

Dakić

Spurgeon

et al. 2022

Journal of Medical Virology

View full text Add to dashboard Cite

The high-risk human papillomaviruses (HPV-16, -18) are critical etiologic agents in human malignancy, most importantly in cervical cancer. These oncogenic viruses encode the E6 and E7 proteins that are uniformly retained and expressed in cervical cancers and required for maintenance of the tumorigenic phenotype. The E6 and E7 proteins were first identified as targeting the p53 and pRB tumor suppressor pathways, respectively, in host cells, thereby leading to disruption of cell cycle controls. In addition to p53 degradation, a number of other functions and critical targets for E6 have been described, including telomerase, Myc, PDZ-containing proteins, Akt, Wnt, mTORC1, as well as others. In this study, we identified Amplified in Breast Cancer 1 (AIB1) as a new E6 target. We first found that E6 and hTERT altered similar profiling of gene expression in human foreskin keratinocytes (HFK), independent of telomerase activity. Importantly, AIB1 was a common transcriptional target of both E6 and hTERT. We then verified that high-risk E6 but not low-risk E6 expression led to increases in AIB1 transcript levels by real-time RT-PCR, suggesting that AIB1 upregulation may play an important role in cancer development. Western blots demonstrated that AIB1 expression increased in HPV-16 E6 and E7 expressing (E6E7) immortalized foreskin and cervical keratinocytes, and in three of four common cervical cancer cell lines as well. Then, we evaluated the expression of AIB1 in human cervical lesions and invasive carcinoma using immunohistochemical staining. Strikingly, AIB1 showed positivity in the nucleus of cells in the immediate suprabasal epithelium, while nuclei of the basal epithelium were negative, as evident in the Cervical Intraepithelial Neoplasia 1 (CIN1) samples. As the pathological grading of cervical lesions increased from CIN1, CIN2, CIN3 carcinoma in situ and invasive carcinoma, AIB1 staining increased progressively, suggesting that AIB1 may serve as a novel histological biomarker for cervical cancer development. For cases of invasive cervical carcinoma, AIB1 staining was specific to cancerous lesions.Increased expression of AIB1 was also observed in transgenic mouse cervical

show abstract

AIB1 predicts tumor response to definitive chemoradiotherapy and prognosis in cervical squamous cell carcinoma

Cited by 4 publications

References 46 publications

SRC-3, a Steroid Receptor Coactivator: Implication in Cancer

SRC-3, a Steroid Receptor Coactivator: Implication in Cancer

An integrative pan-cancer analysis illustrating the key role of LRP11 in cervical cancer

AIB1 is a novel target of the high‐risk HPV E6 protein and a biomarker of cervical cancer progression

Contact Info

Product

Resources

About